The Hopkins ACTU proposal is designed to take maximum advantage of the Hopkins AIDS Care Program, scientific resources of this institution, priorities of the Program Office and statewide needs for its underserved population. Major changes in ACTU activities during the past two years reflect emphasis areas of the Division of AMS including studies of opportunistic infections and inclusion of underrepresented populations. Accomplishments during the prior grant period include: enrollment of 596 patients which ranks eighth among all ACTUs; enrollment of 225 participants during the last year which ranks second; enrollment of 175 blacks, which ranks first; development of an 01 study team in 1989 with subsequent enrollment of 175 patients in 12 OI protocols; protocol chair for 14 ACTG protocols; development of a unique minority outreach program and networking of ACTU resources that easily reach 80-90% of persons with known HIV infection in the metropolitan Baltimore area (with the potential of adding Washington DC to our catchment area). The major referral network for our ACTU now includes the Hopkins AIDS Care Program under our direct supervision (2500 patients), two STD Clinics (1750 identified patients with HIV infection) and the Maryland Division of Corrections (estimated 1600 patients with HIV infection). Demographics of these 5250 patients show 81% are black, 25% are women, and 56% have IV drug use as their risk factor. Our referral network also includes community physicians who have previously provided 37% of ACTU participants. Emphasis areas of the Hopkins ACTU include: 1) the Neurology Department supervised by Dr. R. Johnson with Dr. McArthur as our continued link; 2) Oncology with Dr. R. Ambinder, Director of the Hopkins Lymphoma Service; 3) Dr. M.L. Clements, Director of the Hopkins AIDS Vaccine Evaluation Unit; 4) Dr. H. Francis, a minority physician who leads our minority outreach initiative; 5) Dr. P. Lietman, Director of Clinical Pharmacology, who supervises our phase I trials. The ACTU has been a critical resource for Hopkins and for Maryland in scientific contributions, for improving access to research for underserved populations and for optimal management of HIV infection through statewide linkages.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027668-09
Application #
2064004
Study Section
Special Emphasis Panel (SRC (35))
Project Start
1986-06-30
Project End
1995-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Mathad, Jyoti S; Gupte, Nikhil; Balagopal, Ashwin et al. (2016) Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr 73:123-9
Natsag, J; Kendall, M A; Sellmeyer, D E et al. (2016) Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density. HIV Med 17:196-205
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8
Longenecker, Chris T; Kitch, Douglas; Sax, Paul E et al. (2015) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69:168-77
Gupta, Samir K; Kitch, Douglas; Tierney, Camlin et al. (2014) Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infect Dis 1:ofu003
Erlandson, Kristine Mace; Kitch, Douglas; Tierney, Camlin et al. (2014) Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 28:1451-61
Wyatt, Christina M; Kitch, Douglas; Gupta, Samir K et al. (2014) Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 67:36-44
McComsey, Grace A; Kitch, Douglas; Sax, Paul E et al. (2014) Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 65:167-74
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6

Showing the most recent 10 out of 88 publications